Evidence map›Paper›PMID 30003813›Full record

ArticleHuman gene therapy2019

Urocortin 3 Gene Transfer Increases Function of the Failing Murine Heart.

Dimosthenis Giamouridis, Mei Hua Gao, N Chin Lai, Zhen Tan, Young Chul Kim, Tracy Guo, Atsushi Miyanohara, Matthijs W Blankesteijn, Erik A L Biessen, H Kirk Hammond

Open access · greenAbstract read
In one paragraph

Article in Human gene therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Gene- and cell-based therapy in cardiovascular diseases.Journal of cardiovascular pharmacology · 2025
    Article
  2. Review
  3. Review
  4. Review
  5. Current Landscape of Heart Failure Gene Therapy.Journal of the American Heart Association · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Dimosthenis Giamouridis1 Veterans Affairs San Diego Healthcare System, San Diego, California; RWTH Aachen, Aachen, Germany.
Mei Hua Gao1 Veterans Affairs San Diego Healthcare System, San Diego, California; RWTH Aachen, Aachen, Germany.
N Chin Lai1 Veterans Affairs San Diego Healthcare System, San Diego, California; RWTH Aachen, Aachen, Germany.
Zhen Tan1 Veterans Affairs San Diego Healthcare System, San Diego, California; RWTH Aachen, Aachen, Germany.
Young Chul Kim1 Veterans Affairs San Diego Healthcare System, San Diego, California; RWTH Aachen, Aachen, Germany.
Tracy Guo1 Veterans Affairs San Diego Healthcare System, San Diego, California; RWTH Aachen, Aachen, Germany.
Atsushi Miyanohara2 Department of Medicine, University of California San Diego, San Diego, California; RWTH Aachen, Aachen, Germany.
Matthijs W Blankesteijn3 Department of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht University, Maastricht, The Netherlands; and RWTH Aachen, Aachen, Germany.
Erik A L Biessen3 Department of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht University, Maastricht, The Netherlands; and RWTH Aachen, Aachen, Germany.
H Kirk Hammond1 Veterans Affairs San Diego Healthcare System, San Diego, California; RWTH Aachen, Aachen, Germany.
VA San Diego Healthcare System · USMaastricht University · NLRWTH Aachen University · DE

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
Vector Production CoreP01HL066941 · NHLBI · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI HAMMOND, H. KIRK · 2001 to 2017
$34.8M
Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8R42HL122038 · NHLBI · RENOVA THERAPEUTICS, INC. · PI HAMMOND, H. KIRK · 2014 to 2017
$1.8M
Translational Studies of Paracrine CV Gene TransferI01BX001515 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI HAMMOND, H. KIRK · 2012 to 2015
–
Urocortin 2 Gene Transfer for Heart Failure with Preserved Ejection FractionI01BX003774 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI HAMMOND, H. KIRK · 2017 to 2025
–
BLRD VA I01 BX001515BLRD VA I01 BX003774NHLBI NIH HHS P01 HL066941NHLBI NIH HHS R42 HL122038NIAID NIH HHS P30 AI036214
6 · The paper itself

Abstract

Peptide infusions of peptides the corticotropin releasing factor family, including urocortin 2, stresscopin, and urocortin 3 (UCn3), have favorable acute effects in clinical heart failure (HF), but their short half-lives make them unsuitable for chronic therapy. This study asked whether UCn3 gene transfer, which provides sustained elevation of plasma UCn3 levels, increases the function of the failing heart. HF was induced by transmural left ventricular (LV) cryoinjury in mice. LV function was assessed 3 weeks later by echocardiography. Those with ejection fractions (EF) <40% received intravenous saline or intravenous adeno-associated virus type-8 encoding murine UCn3 (AAV8.mUCn3; 1.9 × 10

Indexed as

Gene ExpressionGenetic TherapyGene Transfer TechniquesTransgenesAnimalsApoptosisBiomarkersCalciumDependovirusDisease Models, AnimalEchocardiographyFemaleFibrosisGene OrderGenetic VectorsHeart FailureBiomarkersCalciumUcn3 protein, mouseUrocortinsAAV8gene therapyheart failure with reduced EFSERCA2a

Identifiers

PMID30003813
PMCPMC6343192
OpenAlexW2883512683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.